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Abstract
Purpose: To analyse the appearance of primary and recurrent malignant peripheral nerve sheath tumours (MPNSTs) 
in magnetic resonance imaging (MRI) with a focus on configuration, and to assess the occurrence of loco-regional 
post-treatment changes and metastases during post-treatment follow-up.
Material and methods: Twenty patients with histologically proven MPNST underwent post-treatment 1.5 T MRI. Pri-
mary and recurrent MPNSTs were examined for configuration, contrast enhancement, extent, and signal intensity 
in MRI. Loco-regional post-treatment changes and information on metastases were extracted from the follow-up.
Results: MPNSTs occurred most often in the extremities (p = 0.006). Twenty per cent (n = 4) of the patients devel-
oped recurrences, with a total of 24 lesions. Recurrent MPNSTs were significantly smaller than primary MPNSTs 
(p = 0.003). Primary MPNSTs mostly occurred unifocally as multilobulated or ovoid and heterogeneous lesions 
with mostly well-defined borders. Recurrent MPNSTs purely occurred multifocally as mostly nodular (p < 0.001), 
multilobulated, or ovoid lesions. 80%, 65% and 30% of the patients showed post-treatment subcutaneous oedema 
(p = 0.002 to 0.03), muscle oedema (p = 0.02), and seroma, respectively. Twenty-five per cent (n = 5) of patients 
presented metastases during follow-up. The relative risk in patients with recurrences to develop lung or lymph node 
metastases is eightfold (p = 0.056).
Conclusions: While primary MPNSTs mostly appear unifocally as multilobulated or ovoid lesions, recurrent MPNSTs 
purely occur multifocally as mostly nodular lesions. Subcutaneous and muscle oedema are very common loco- 
regional post-treatment changes. Patients with recurrences have a higher risk for lung and lymph node metastases.
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Introduction
Malignant peripheral nerve sheath tumours (MPNST) 
are rare and highly aggressive neoplasms arising from 
Schwann cells [1,2]. The expected incidence of MPNST 
is reported to be 0.1/100,000 per year [2,3], and they ac-
count 3-10% of all soft tissue tumours [2-5]. 40–50% of 
MPNST are associated with neurofibromatosis type 1 
(NF-1) gene mutation [2,6]. In about 50% of the patients 
MPNST occur sporadically [7]. MPNST have a high po-
tential for local recurrence and a high risk for metastatic 
spread [6]. They most often appear in the limbs, trunk/
retroperitoneum, and head/neck region of middle-aged 
to elderly adults [7]. MPNST responds poorly to chemo- 
or radiotherapy; therefore, surgery with wide resection 
margins is the most comonly performed curative treat-
ment [1,6,8,9]. As MPNST are very rare neoplasms, there 
are very few data regarding imaging of MPNST. There-
fore, the aim of this study was to analyse the appearance 
of MPNSTs in magnetic resonance imaging (MRI) with 
 MPNST in MRI follow-up
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a focus on configuration and to assess the occurrence of 




From 248 patients with malignant soft-tissue sarcoma 28 
consecutive patients with histologically proven diagnosis 
of MPNST between 2012 and 2018 were reviewed. Eight 
patients were excluded due to insufficient imaging data. 
Four of these patients had no follow-up imaging at our 
institution and four patients underwent other examina-
tions than MRI. The twenty remaining patients under-
went MRI follow-up for a minimum of one year (equiva-
lent to four MRI follow-up scans) at our institution after 
resection of primary MPNST. The primary and recurrent 
tumours were radiographically examined for signal inten-
sity, contrast enhancement (intensity, heterogeneous/ho-
mogenous), configuration, extent, and limitation in MRI. 
As general epidemiological data, the age of the patients at 
primary diagnosis, the localisation of the primary and re-
current tumours, and the recurrence-free MRI follow-up 
interval were analysed. As loco-regional post-treatment 
soft-tissue changes, subcutaneous and muscle oedema, 
post-operative seroma, reactive lymphadenopathy, bone 
oedema, and synovialitis were included. Additionally, the 
patients were screened for information about metastases.
Magnetic resonance imaging was performed with a 1.5 
Tesla MRI system (MAGNETOM Symphony, Siemens 
Healthineers). The MRI protocol was performed with the 
following sequences: axial T2-weighted (TE: 64-114 ms, 
TR: 3010-5840 ms, FOV: 22-44 cm, SD: 5-6 mm), axial 
T1-weighted (TE: 10-14 ms, TR: 587-868 ms, FOV: 22-44 cm, 
SD: 5-6 mm), axial proton density-weighted (PDw) (TE: 
26-36 ms, TR: 2740-4610 ms, FOV: 22-40 cm, SD: 5-6 mm), 
coronal Turbo-Inversion Recovery-Magnitude (TIRM) 
(TE: 68-77 ms, TR: 4410-6980 ms, FOV: 37-45 cm, SD: 
4-6 mm), axial (1012 ms, TR: 645-865 ms, FOV: 22-44 cm, 
SD: 5-6 mm), coronal (TE: 10-13 ms, TR: 533-1440 ms, 
FOV: 37-45 cm, SD: 4-6 mm), and sagittal (TE: 10-13 ms, 
TR: 577-866 ms, FOV: 22-37 cm, SD: 5-10 mm) T1-weight-
ed after application of IV contrast agent.
Two dedicated sarcoma radiologists with a mini-
mum of five years of experience in sarcoma diagnostics 
reviewed each MRI with findings reached by consensus.
Statistical analysis
If not indicated otherwise, data are given as median values 
with range (minimum to maximum) or mean with stan-
dard deviation (SD). Parametric and nonparametric tests 
to compare group values (χ2 test, Mann-Whitney U test, 
ANOVA) were performed as indicated. Specificity, sensi-
tivity, and area under the curve (AUC) were determined 
using 2 × 2 tables. Furthermore, risk ratios (RR) for the 
determination of relative risks were analysed. Statistical 
significance for all tests was set at a level of p < 0.05. Sta-
tistical analysis was done using the IBM-SPSS version 22.0 
software package (IBM, Armonk, NY, USA).
Ethics approval
The study was conducted in accordance with, and was ap-
proved by, the responsible Ethics Committee.
Results
The mean age of the patients was 49 years (SD: 19, min.: 
16, max.: 81). Recurrences occurred after a mean of 
26 months (SD: 23.3, min.: 9, max.: 60). MPNST occurred 
most often in the axilla (20%), followed by the thigh (15%), 
elbow, and lower leg (10% each). Altogether MPNST 
arose significantly most often in the extremities (13 cases; 
p = 0.006). Recurrent MPNST purely occurred in the ax-
illa, thigh, and hip (Figure 1). In four of 20 patients we 
found recurrences of MPNST in MRI follow-up (20%), 
with 24 lesions altogether. Recurrent MPNST were signif-
icantly smaller than primary MPNST in mean diameter 
(p = 0.003). The main appearance of primary MPNST 
was multilobulated (Figure 2) and ovoid with heteroge-
neous contrast enhancement and well-defined borders 
(p = 0.002). In one case primary MPNST presented as in-
filtrative and in another case with a few contrast enhance-
ments (Table 1). All primary MPNSTs presented unifocally. 
Recurrent MPNSTs purely occurred multifocally as mostly 
nodular lesions (p < 0.001, Figure 3) with homogenous 
contrast enhancement and well-defined borders (Table 2), 
but also multilobulated/heterogeneous (Figure 4) or ovoid. 
All primary and recurrent tumours presented with muscle 
iso-intense T1-weighted and high PD-weighted and TIRM 
signal. The overall most common loco regional post-treat-
ment changes after resection of MPNST were subcutane-
ous oedema (80%; p = 0.002 to 0.03), followed by muscle 
oedema (65%; p = 0.02) and post-operative seroma (30%; 
p = 0.04). In patients with the presence of post-operative 
Figure 1. Main localisations of primary and recurrent malignant peripheral 








Axilla Thigh Elbow Lower leg Pelvis
Primary Recurrences 
Sam Sedaghat, Frederick Schmitz, Martin Grözinger, Maya Sedaghat  
e198 © Pol J Radiol 2020; 85: e196-e201
seroma the risk for recurrence was non-significantly high-
er (RR = 2; 95% CI: 0.55-7.3; p = 0.29; Table 3). 
Metastases were found in five patients (25%) with 
three cases of lung and lymph node metastases, respec-
tively, and one case each of pleural, bone, chest wall, and 
liver metastases. Patients with recurrences had a non-sig-
nificantly higher risk for lung and lymph node metastases 
(RR = 8, 95% CI: 0.955-67.7, p = 0.056; Table 4).
Discussion
In this study we mainly analysed the appearance of primary 
and recurrent MPNST in MRI with a focus on configuration, 
and assessed the occurrence of loco-regional post-treatment 
changes and metastases during post-treatment follow-up. 
Until now there have been only a few publications on imag-
ing of MPNST because MPNST is a very rare disease [10].
The median recurrence-free follow-up interval in our 
study is 54 months. This has to be distinguished from the 
overall recurrence-free follow-up interval, which is often 
higher due to the lack of MRI follow-up data. Actually, 
an MRI follow-up interval of five years after resection of 
the primary tumour is intended [11], but it is frequently 
observed that a lot of patients do not undergo their total 
follow-up in one and the same radiological department.
Figure 2. Primary malignant peripheral nerve sheath tumour at 1.5 Tesla magnetic resonance imaging: A) coronary proton density weighted; B) axial 
T1-weighted with fat saturation after application of IV contrast agent of the lower leg of a 48-year-old female patient. The tumour presents as a multilob-
ulated mass with well-defined borders and heterogenous contrast enhancement (white arrow)
A B
Table 1. Magnetic resonance imaging contrast agent behaviour, appearance, and limitation of 8 consecutive primary malignant peripheral nerve sheath 









P – primary Homogenous Heterogenous Intensity Sharply Infiltrative
P1 – X +++ X – Ovoid 56 51
P2 – X ++ X X Multilobulated 81 58
P3 – X +++ X – Multilobulated 35 70
P4 – X ++ X – Multilobulated 22 81
P5 – X +++ X – Multilobulated 48 94
P6 – X + X – Ovoid 74 19
P7 – X ++ X – Ovoid 36 37
P8 – X +++ X – Multilobulated 43 67
p-value – 0.002 0.18
Mean, SD 49.4, 20.1 59.6, 24.0
 MPNST in MRI follow-up
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Figure 3. Recurrent malignant peripheral nerve sheath tumour at 1.5 T magnetic resonance imaging of the left thigh of a 57-year-old patient (T1-weighted 
with fat saturation after application of IV contrast agent) in axial (A) and sagittal (B) view. The tumour mass in the left thigh appears multilobulated with 
heterogenous contrast enhancement (white arrow) and infiltrative behaviour (white arrow head)
A B
Table 2. Magnetic resonance imaging contrast agent behaviour, appearance and limitation of 4 consecutively cases of recurrent malignant peripheral 
nerve sheath tumours (MPNST) with altogether 24 lesions. Additionally, the age of manifestation in years and the mean diameter of the primary tumour 










R – recurrence Homogenous Heterogenous Intensity Sharply Infiltrative All multifocal
R1 – X ++ X X Multilobulated (2) 21 19
X – ++ X – Nodular (2) 4
X – ++ – X Streaky (1) 8
X – ++ X X Ovoid (3) 11
R2 X – ++ X – Multiple nodular (10) 52 5
R3 – X ++ X X Multilobulated 57 21
X – ++ X – Nodular (2) 6.5
R4 – X ++ X X Multilobulated (1) 36 14
– X ++ X – Ovoid (1) 10
X – ++ X – Nodular (1) 5
p-value – – Nodular: p < 0.001
Mean, SD 41.5, 16.3 –
Figure 4. Recurrent malignant peripheral nerve sheath tumour at 1.5 T magnetic resonance imaging of the pelvis of a 57-year-old patient (T1-weighted 
with fat saturation after application of IV contrast agent) in axial view. A and B show two nodular lesions next to the sacrum with homogenous contrast 
enhancement and well-defined borders (white and black arrows)
A B
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risk ratio (RR); 
p-value
Subcutaneous tissue oedema 16 (80)
0.002
0.03
3 (75) 13 (81) –
Muscle oedema 13 (65)
0.02
2 (50) 11 (68) –
Post-operative seroma 6 (30) 2 (50) 4 (25) RR = 8; p = 0.056
Lymphadenopathy 4 (20) – 4 (25) –
Bone oedema 1 (5) – 1 (6) –
Muscle abscess 1 (5) 1 (25) – –
Synovialitis 1 (5) – 1 (6) –
Statistical significance: p < 0.05
Table 4. Metastases occurred within magnetic resonance imaging follow-up in total and in patients with and without recurrences. The relative risk ratio 




Patients with recurrence 
(4 patients)
n (%)
Patients without recurrence  
(16 patients)
n (%)
Relative risk ratio (RR); 
p-value
Lung 3 (15) 2 (50) 1 (6) 8; 0.056
Lymph node 3 (15) 2 (50) 1 (6) 8; 0.056
Bone 1 (5) 1 (25) 1 (6) –
Pleura 1 (5) 1 (25) – –
Chest wall 1 (5) 1 (25) – –
Liver 1 (5) – 1 (6) –
MPNST is reported to be mostly located in the extrem-
ities and the trunk but may also occur in other sites like the 
head and neck [12,13]. In our study the extremities were 
the primary site of MPNST as well, followed by the axilla.
Magnetic resonance imaging is the favoured imaging 
modality for pre- and post-treatment evaluation of soft-
tissue tumours [14]. The application of contrast agent is not 
required in all cases, but contrast enhancement may help 
to distinguish between post-treatment changes and the 
recurrent tumour [14,15]. Nevertheless, the specificity of 
MRI for the detection of recurrences of soft-tissue tumours 
is reported to be moderate [16]. In contrast, Park C. et al. 
described a high sensitivity and specificity of MRI for the 
detection of recurrent soft-tissue sarcoma (90% and 97.7%, 
respectively) [17]. Twenty per cent of our patients developed 
local recurrences within MRI follow-up, with 24 lesions al-
together. Local recurrences are reported to occur in 10-50% 
of all soft-tissue sarcomas [18] and in 35% of patients with 
MPNSTs [2], after resection of the primary tumours.
In our study recurrent MPNSTs presented significantly 
smaller than the primary tumours. A reason for this may 
be the earlier detection of the recurrent tumours within 
the MRI follow-up scans, which are routinely performed 
at intervals of 3-12 months. The mean diameter of prima-
ry MPNST is reported to range from 1 to 20 cm (median 
size of 8-12 cm) [5,19,20].
Previous studies mainly assess MRI features of pri-
mary MPNST with a focus on MRI signal characteristics. 
In this study we mainly focused on the MRI appearance 
of both primary and recurrent MPNST. MPNST presents 
with high signal intensity in T2 STIR and PD FS and low 
signal intensity in T1 sequences [5,19,21]. Furthermore, 
MPNST is reported to appear in different shapes with 
mostly heterogeneous appearance and well-defined mar-
gins [5,19,20]. MPNST may also present as ovoid with 
uniform enhancement [19,20]. In our study we found two 
main appearances of primary MPNSTs: multilobulated 
and ovoid, with both heterogeneous/marked contrast en-
hancement and well-defined borders. In only one case pri-
mary MPNST presented with infiltrative and in another 
case with only a few contrast enhancements. Against this, 
recurrent MPNSTs purely occurred multifocal as mostly 
nodular lesions. As a result, radiologists should look for 
a minimum of a second lesion after detection of any re-
current MPNST lesion within MRI follow-up. 
As mentioned, MRI plays an important role in the 
postoperative evaluation of soft-tissue changes. Differen-
tiation between post-treatment soft-tissue changes and 
tumour recurrences has to be made, which is often prob-
lematic [22]. It is reported that post-treatment bone and 
soft-tissue changes are often apparent on MRI [18]. In our 
study 80% of the patients present with subcutaneous oe-
 MPNST in MRI follow-up
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dema, followed by muscle oedema (65%) and post-opera-
tive seroma (30%). Post-operative seromas are reported to 
occur in approximately 17-19% of cases after resection of 
soft-tissue sarcomas [22-24]. In addition, post-operative 
seromas normally appear homogenous and well-defined 
with rim contrast enhancement [18]. Furthermore, 37% of 
patients with soft-tissue tumours may present with bone 
marrow oedema [25]. In our study we detected one pa-
tient with bone marrow oedema after resection of primary 
MPNST.
Previous data describe that 39% of the patients with 
MPNST present with distant metastasis, mainly to the 
lung (28%), but also to the bone (5%), liver (2%), and 
lymph nodes (1%) [2]. Lung metastases occur in about 
20% of patients diagnosed with soft-tissue sarcoma [26]. 
We found metastases in five patients, with three cases of 
lung and lymph node metastases, respectively. Especially 
patients with recurrence have a non-significantly higher 
risk for lung and lymph node metastases. 
Conclusions
While primary MPNSTs appear unifocally as multilobulat-
ed or ovoid and heterogeneous lesions, recurrent MPNSTs 
purely occur multifocally as mainly nodular lesions. There-
fore, radiologists should look for a minimum of a second 
lesion after detection of any recurrent MPNST lesion. Post-
treatment subcutaneous and muscle oedema are common 
occurrences in MRI follow-up. Patients with recurrences 
have a higher risk for lung and lymph node metastases.
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